Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 141: Nivolumab vs Investigator's Choice in Recurrent or Metastatic SCCHN
NCT02105636Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2014
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of nivolumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Bristol Myers Squibb. Started May 2014; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02105636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105636.